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LETTERS TO THE EDITOR
The opinions expressed by correspondents in this column 
are in no way endorsed by the Editors or The Royal 
Australian College of General Practitioners. 
thousands are never enough. They need to know 
that while most people who attempt cheating 
walk away feeling as if they have gotten away 
with it, just one puff and up to 50% of a4b2-
type nicotinic receptors become occupied by 
nicotine.6 And it won’t be long before the lapsed 
patient who has lapsed finds their brain wanting, 
conspiring to obtain or even beg for more.
As for the tease of e-cigarettes, vaping and 
cleaner delivery, remind them that being free is 
vastly more doable and far more wonderful than 
their wanting for that next fix will suggest. Ask 
them why they would devote weeks or months 
towards adjusting to a new form of nicotine 
delivery when they could become 100% nicotine-
clean and move beyond peak withdrawal within 
72 hours. Just 1 hour and challenge at a time, yes 
they can!  
John R Polito, JD 
Nicotine Cessation Educator
WhyQuit.com
South Carolina US
Competing interests:  Pro bono director of 
WhyQuit, an abrupt nicotine cessation website, 
and author of Freedom from Nicotine – The 
Journey Home.
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Reply
Dear Editor
We thank Dr Polito for his response to our 
article. We do not believe that offering help 
to people who smoke when they present in 
general practice, or other clinical settings, in 
any way undermines those smokers who prefer 
to try to quit without assistance from a health 
professional. It is also important to note that 
population surveys, such as the study by Doran 
et al,1 inevitably have risks of selection bias that 
may lead to underestimation of the effectiveness 
of smoking cessation treatment.2–5 Clinical 
trials remain the most reliable measure of 
effectiveness and have been conducted in a range 
of settings with a variety of populations. 
We agree with Dr Polito that nicotine is a 
highly addictive drug and given the fact that 
dependence can be rapidly re-established after 
further exposure, the not-a-puff rule makes good 
sense and indeed we recommend this approach 
in our article. 
The issue of whether e-cigarettes have a 
possible role in harm reduction for people who are 
unable to stop using nicotine is quite a separate 
one and a question that needs further research. 
Nicholas Zwar
School of Public Health and Community Medicine, 
University of NSW 
Colin Mendelsohn
Brain and Mind Institute, University of Sydney
Robyn Richmond
School of Public Health and Community Medicine, 
University of NSW
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Tobacco smoking: options 
for helping smokers to quit
Dear Editor
Zwar, Mendelsohn and Richmond’s exclusive 
reliance on nicotine replacement therapy (NRT) 
clinical trial efficacy findings in their article 
‘Tobacco smoking: options for helping smokers 
to quit’1 (AFP June 2014) leaves readers with 
the false impression that clinical efficacy has 
translated into population level effectiveness.
Doran et al 20062 involved a cross-sectional 
survey of 8333 Australian general practice 
patients. They found that cold-turkey quitting 
was roughly twice as effective as NRT. They 
also found that cold-turkey quitting accounted 
for 88% of all successful quitters (1942 of 
2207).2 More recently, a July 2013 US Gallup 
Poll found that only 8% of ex-smokers credited 
any quit smoking product (NRT or prescription 
medication) for their success.3
Imagine the assault on motivation endured 
by the average patient attempting to quit cold 
turkey when nearly every internet quitting site 
repeatedly echoes the authors’ Figure 3 efficacy 
suggestion that they are substantially more likely 
to fail. Although formal study of the keys to 
successful abrupt cessation has been neglected, 
practitioners would be wise to spend a few 
minutes exploring sites devoted exclusively 
to cold-turkey education, counselling and/or 
support.
What is the most critical lesson about abrupt 
cessation physicians can share? I submit that it 
flows from lapse/relapse studies, that ‘the high 
rate of return to regular smoking (88%) once a 
cigarette is tasted suggests that the distinction 
between an initial lapse and full relapse may be 
unnecessary.’4 And let’s not forget that at least 
10% of smokers are consistently identified as 
non-dependent chippers.5
 Patients who smoke need to understand 
that recovery from nicotine dependence is all or 
nothing, that one puff will be too many, while 
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4. West R, Zhou X. Is nicotine replacement therapy 
for smoking cessation effective in the ‘real world’? 
Findings from a prospective multinational cohort 
study Thorax 2007;62:998–1002.
5. Borland R, Partos TR, Cummings KM. Systematic 
biases in cross-sectional community studies may 
underestimate the effectiveness of stop-smoking 
medications. Nic Tob Res 2012;14:1483–87. 
Sentinel lymph node biopsy 
Dear Editor
In their viewpoint article concerning sentinel node 
biopsy (SNB) in melanoma management1 (AFP, 
July 2014), Dixon et al appear to overlook the two 
main conclusions of the Multicenter Selective 
Lymphadenectomy Trial-I (MSLT-I): 
• ‘Biopsy-based staging of intermediate-
thickness or thick primary melanomas … 
identifies patients with nodal metastases 
who may benefit from immediate complete 
lymphadenectomy.’ 
• ‘Biopsy-based management prolongs … 
melanoma-specific survival for patients with 
nodal metastases from intermediate-thickness 
melanomas.’2 
The authors acknowledge that SNB is a 
diagnostic procedure but fail to realise that 
diagnostic procedures only have prognostic and 
therapeutic value in patients in whom the pursued 
abnormality is indeed found, eg a lymph node biopsy 
for suspected lymphoma will only lead to treatment 
if the disease is found, and only then can an impact 
on survival be expected. This is also true for SNB. 
Appropriate subsequent therapy can only improve 
survival in patients with an involved sentinel node. 
Therefore, the most important outcome of MSLT-I 
concerns the patients with intermediate thickness 
melanomas in whom lymph node metastasis 
is found. In this prespecified target population, 
management determined by SNB substantially 
increases the survival rate compared to those who 
did not undergo SNB staging and developed palpable 
nodal disease later (10-year survival 62% vs 41%). 
Such an improvement in survival is exceptional in 
oncology and cannot be ignored.
The MSLT-I final report also shows that occult 
metastases in lymph nodes progress to clinically 
relevant disease over time. SNB-positive patients 
have a 12–20% risk of having more involved nodes. 
Whether a completion node dissection is required in 
all these patients is not known. This is the subject 
of another trial, MSLT-II, but it appears prudent to 
perform completion lymph node dissection until 
the outcome of this study is known. 
We conclude that there is now convincing 
evidence to recommend SNB in patients with a 
clinically localised melanoma of intermediate 
Breslow thickness and to consider the procedure 
in patients with a thinner or thicker lesion. The 
American Society of Clinical Oncology and the 
Society of Surgical Oncology, the most respected 
medical and surgical oncology groups in the 
world, made the same recommendation in their 
joint, evidence-based guideline.3
Dr Omgo Nieweg
Melanoma Institute Australia, North Sydney, 
NSW
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Reply
Dear Editor
Thank you for the opportunity to respond to 
the suggestion that a sub analysis within 
the multicentre selective lymphadenectomy 
trial (MSLT-I) data1,2 justifies continued usage 
of sentinel lymph node biopsy (SLNB) as a 
treatment.
Like any randomised controlled trial (RCT) 
the important data is on an intention to treat 
(ITT) basis. The ITT data is clear. There was no 
10-year melanoma specific survival benefit for 
intervention patients (77%), versus observation 
(76%). Even intermediate thickness melanoma 
patients failed to gain a survival benefit from 
SLNB and completion lymphadenectomy (CL). 
This is a negative study. Examination of sub 
analyses is always fraught with danger. There is 
naturally a wish to try and salvage something of 
clinical relevance from these seminal studies.
So, what of these subanalyses? We agree 
that SLNB gives patients added prognostic 
information; coming with the risks of surgery.3 
More melanoma lymph nodal involvement (MNI) 
occurred in the intervention group (19.9%), 
versus the observation group (17.4%). The 
intervention group MNI comprises SLNB positive 
patients (15.9%) and patients that were biopsy 
negative but later developed nodal disease (4%). 
This demonstrates that the SLNB test is not 
perfect. This discrepancy explains many other 
curious subanalyses
We are asked to compare all in intervention 
patients with MNI (this 19.9%) with observation 
patients that developed MNI later. There is a 
suggested survival advantage in finding MNI early 
(62%), versus waiting for MNI to become clinically 
apparent (41%). But this is an extracted data set from 
an RCT showing no ITT survival benefit. Therefore it 
is not surprising that those in the intervention group 
that never had MNI still had a high ten year mortality 
rate of 17%. This compares unfavourably with 
10-year mortality in the observation group that never 
developed MNI (12.5%!). 
If we are to believe doing an SLNB and finding 
an early positive node saves lives, then we would 
have to believe that having negative SLNB test 
is killing other patients. Of course, neither is the 
case. It is just another example of the serious 
pitfalls in straying from an ITT analysis. 
The current MSLT-II trial will provide further 
useful data. In this trial patients who have a positive 
SLNB are randomised to either CL or observation. 
We encourage patients who have a positive SLNB 
test to consider enrolment in this trial. 
We disagree that SLNB positive patients 
should be invited to proceed to CL outside of 
the MSLT 2 clinical trial. Indeed to encourage 
patients to have this further major procedure 
with a 37% complication rate3 with no apparent 
survival benefit raises ethical and moral 
questions. MSLT-1 has taught us that we need 
to avoid a presumption of surgical benefit. Let us 
not repeat history.
Anthony J Dixon, Alexander Nirenberg
Australasian College of Cutaneous Oncology, 
Belmont, VIC
Stuart Anderson
Maffra Medical Group, Maffra, VIC
Howard K Steinman
Texas A&M Health Science Center College of 
Medicine, Texas, USA
John B Dixon
Baker IDI Heart & Diabetes Institute, Melbourne, VIC
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